BioMarin Pharmaceutical Inc
Closed
SectorHealthcare
54.37 -1.63
Overview
Share price change
24h
Min
54.61
Max
55.91
Income | -61M 45M |
|---|---|
Sales | 224M 990M |
P/E Sector Avg | 155.514 47.946 |
EPS | 0.9 |
Profit margin | 4.523 |
Employees | 3,221 |
EBITDA | 50M 222M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +70% upside |
Next Earnings | 26 Oct 2026 |
|---|
Market Cap | -458M 11B |
|---|---|
Previous open | 56 |
Previous close | 54.37 |
BioMarin Pharmaceutical Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
BioMarin Pharmaceutical Inc Forecast
Price Target
By TipRanks
70% upside
12 Months Forecast
Average 93.15 USD 70%
High 124 USD
Low 60 USD
Based on 22 Wall Street analysts offering 12 month price targets forBioMarin Pharmaceutical Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About BioMarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.
